These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 2314821)
1. Doxorubicin and etoposide in the treatment of advanced measurable breast cancer. Giaccone G; Donadio M; Bonardi G; Testore F; Calciati A Oncology; 1990; 47(2):105-8. PubMed ID: 2314821 [TBL] [Abstract][Full Text] [Related]
2. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614 [TBL] [Abstract][Full Text] [Related]
3. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725 [TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Joss RA; Alberto P; Obrecht JP; Barrelet L; Holdener EE; Siegenthaler P; Goldhirsch A; Mermillod B; Cavalli F Cancer Treat Rep; 1984 Sep; 68(9):1079-84. PubMed ID: 6090014 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263 [TBL] [Abstract][Full Text] [Related]
6. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. Lerner A; Gonin R; Steele GD; Mayer RJ J Clin Oncol; 1992 Apr; 10(4):536-40. PubMed ID: 1548518 [TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer. Palmeri S; Leonardi V; Tamburo De Bella M; Morabito A; Vaglica M; Accurso V; FerraĆ¹ F; Failla G; Agostara B; Massidda B; Valenza R; Fanelli M; Gasparini G Oncology; 2002; 63(3):205-12. PubMed ID: 12381898 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. Spielmann M; Dorval T; Turpin F; Antoine E; Jouve M; Maylevin F; Lacombe D; Rouesse J; Pouillart P; Tursz T J Clin Oncol; 1994 Sep; 12(9):1764-70. PubMed ID: 8083698 [TBL] [Abstract][Full Text] [Related]
9. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. Wallerstein R; Spitzer G; Dunphy F; Huan S; Hortobagyi G; Yau J; Buzdar A; Holmes F; Theriault R; Ewer M J Clin Oncol; 1990 Nov; 8(11):1782-8. PubMed ID: 2121909 [TBL] [Abstract][Full Text] [Related]
11. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Yoh K; Goto K; Ishii G; Niho S; Ohmatsu H; Kubota K; Kakinuma R; Nagai K; Suga M; Nishiwaki Y Cancer; 2003 Sep; 98(5):926-31. PubMed ID: 12942558 [TBL] [Abstract][Full Text] [Related]
12. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. Canellos GP; Petroni GR; Barcos M; Duggan DB; Peterson BA J Clin Oncol; 1995 Aug; 13(8):2005-11. PubMed ID: 7636541 [TBL] [Abstract][Full Text] [Related]
13. [A case report of advanced breast cancer effectively treated with etoposide, adriamycin and cis-platinum combination therapy]. Kurihara T; Teshigawara O; Owada S; Fujii T Gan To Kagaku Ryoho; 1988 Oct; 15(10):2991-4. PubMed ID: 3178243 [TBL] [Abstract][Full Text] [Related]
14. Single-dose etoposide in combination with vincristine and doxorubicin in the treatment of small-cell lung cancer (SCLC). Timothy AR; Calman FM; Bateman NT; Farebrother M; Slevin ML; Bellamy D; Rubens RD; Costello J Semin Oncol; 1985 Mar; 12(1 Suppl 2):45-7. PubMed ID: 2983435 [TBL] [Abstract][Full Text] [Related]
15. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757 [TBL] [Abstract][Full Text] [Related]
17. Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy. Athanassiades P; Bacoyiannes H; Kontoyiannes D Chemioterapia; 1986 Apr; 5(2):125-7. PubMed ID: 3518965 [TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687 [TBL] [Abstract][Full Text] [Related]
20. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. Papandreou CN; Daliani DD; Thall PF; Tu SM; Wang X; Reyes A; Troncoso P; Logothetis CJ J Clin Oncol; 2002 Jul; 20(14):3072-80. PubMed ID: 12118020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]